Alzheimer's Disease And Related Disorders Association, Georgia Chapter, Inc.

The Dementia Discovery Fund (DDF), managed by SV Health Investors, has closed its second fund with $269 million in commitments, bringing its total raised capital to over $550 million for dementia therapeutics development.

K2 Medical Research has established a new clinical trials facility in East Providence, Rhode Island, bringing innovative research opportunities to Southern New England with a primary focus on Alzheimer's disease.

UVA Health researchers discovered that HIV medications called NRTIs significantly reduce Alzheimer's risk, with annual decreases of 6-13% observed across two major health insurance databases.

University of New Mexico researchers have developed a vaccine that generates antibodies against pathological tau protein (pT181), showing efficacy in both mice and non-human primates with strong immune responses.

UC Irvine researchers have developed a groundbreaking therapy using CRISPR-edited microglia that can detect and target amyloid plaques in Alzheimer's disease, delivering therapeutic proteins precisely where needed.

Washington University School of Medicine initiates a pioneering trial of remternetug, a monoclonal antibody designed to prevent Alzheimer's disease by targeting amyloid-beta before symptom onset.

• Eisai and Biogen's experimental Alzheimer's drug lecanemab demonstrated a 27% reduction in cognitive decline over 18 months in a large-scale clinical trial of early-stage patients. • The drug successfully cleared amyloid beta in 68% of treated participants, though safety concerns arose with 12.6% experiencing brain swelling and 14% showing microhemorrhages. • Clinical benefits varied among genetic subgroups, with APOE4 homozygous patients showing limited response on primary endpoints, while secondary measures demonstrated 23-37% improvement across patient groups.

WashU Medicine initiates groundbreaking international trial testing Eli Lilly's remternetug in young adults as young as 18, targeting Alzheimer's prevention up to 25 years before expected symptom onset.

• Research indicates a critical 10-year window exists between the initial accumulation of abnormal brain proteins and the onset of noticeable Alzheimer's symptoms, providing opportunities for early intervention. • Mild Cognitive Impairment (MCI), the early symptomatic stage of Alzheimer's, typically lasts around 4 years before progressing to clinical dementia, with higher-risk patients showing faster progression. • Emerging evidence supports the role of lifestyle interventions, including moderate-intensity aerobic exercise, cognitive engagement, and proper sleep management in potentially slowing disease progression during early stages.

A long-term safety analysis of omaveloxolone, the first FDA-approved treatment for Friedreich ataxia, shows a positive safety profile, offering reassurance for its use.